Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04959981 · ClinicalTrials.gov registry record · Phase 1
A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC
A Phase 1 study, sponsored by Erasca.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT04959981 is a Phase 1 study that has completed, run by Erasca. The registered enrollment target is 24 participants.
The verdict
NCT04959981, a Phase 1 study, has completed, sponsored by Erasca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
* To evaluate the safety and tolerability of escalating doses of ERAS-007 or ERAS-601 in combination with other cancer therapies in study participants with advanced non-small cell lung cancer (NSCLC). * To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 or ERAS-601 administered in combination with other cancer therapies. * To evaluate the antitumor activity of ERAS-007 or ERAS-601 in combination with other cancer therapies. * To evaluate the PK profiles of ERAS-007 or ERAS-601 and other cancer therapies when administered in combination.
Interventions
- DRUG Osimertinib
- DRUG Sotorasib
- DRUG ERAS-601
- DRUG ERAS-007
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2021-09-02 |
| Est. Completion | 2023-04-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04959981
The ClinicalTrials.gov registry entry for NCT04959981 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Erasca, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Osimertinib is the first listed.
NCT04959981 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04959981 about?
NCT04959981 is a clinical study titled "A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC". * To evaluate the safety and tolerability of escalating doses of ERAS-007 or ERAS-601 in combination with other cancer therapies in study participants with advanced non-small cell lung cancer (NSCLC). * To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 or ERAS-60...
What is the current status of trial NCT04959981?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2021-09-02. Estimated completion is 2023-04-27.
What interventions are being tested in trial NCT04959981?
The interventions under investigation include: Osimertinib (DRUG), Sotorasib (DRUG), ERAS-601 (DRUG), ERAS-007 (DRUG).
Who is sponsoring clinical trial NCT04959981?
This trial is sponsored by Erasca, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.